A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 1
134
about 4.1 years
18+
Male only
11 sites in CA, FL, IL +7
What this study is about
Researchers are testing the safety and tolerability of AZD2284, AZD2287, and AZD2275. The trial will involve escalating doses of AZD2284 to determine its safety and effectiveness in patients with metastatic castration-resistant prostate cancer.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take AZD2275
- 2.Take AZD2284
- 3.Take AZD2287
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of participants with Dose Limiting Toxicities (DLTs), Number of participants with adverse event (AEs)
Secondary: Duration of Response (DoR), Half-life (t1/2), Maximum observed drug concentration (Cmax), Overall Response Rate (ORR), Overall Survival (OS), Pharmacokinetic Clearance, Radiographic Progression Free Survival (rPFS)
Oncology